NO20003785D0 - Anvendelse av 2-amino-6-trifluormetoksy-benzotiazol for prevensjon eller terapi av cerebellum dysfunksjon - Google Patents

Anvendelse av 2-amino-6-trifluormetoksy-benzotiazol for prevensjon eller terapi av cerebellum dysfunksjon

Info

Publication number
NO20003785D0
NO20003785D0 NO20003785A NO20003785A NO20003785D0 NO 20003785 D0 NO20003785 D0 NO 20003785D0 NO 20003785 A NO20003785 A NO 20003785A NO 20003785 A NO20003785 A NO 20003785A NO 20003785 D0 NO20003785 D0 NO 20003785D0
Authority
NO
Norway
Prior art keywords
prevention
benzothiazole
trifluoromethoxy
therapy
amino
Prior art date
Application number
NO20003785A
Other languages
English (en)
Other versions
NO327819B1 (no
NO20003785L (no
Inventor
Andrees Bohme
Alain Boireau
Thierry Canton
Assunta Imperato
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of NO20003785D0 publication Critical patent/NO20003785D0/no
Publication of NO20003785L publication Critical patent/NO20003785L/no
Publication of NO327819B1 publication Critical patent/NO327819B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NO20003785A 1998-02-06 2000-07-24 Anvendelse av riluzol eller et farmasoytisk akseptabelt salt derav NO327819B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9801402A FR2774592B1 (fr) 1998-02-06 1998-02-06 Application du 2-amino-6-trifluoromethoxybenzothiazole pour la prevention ou le traitement des dysfonctionnements du cervelet
PCT/FR1999/000230 WO1999039710A1 (fr) 1998-02-06 1999-02-03 Application du 2-amino-6- trifluoromethoxy- benzothiazole pour la prevention ou le traitement des dysfonctionnements du cervelet

Publications (3)

Publication Number Publication Date
NO20003785D0 true NO20003785D0 (no) 2000-07-24
NO20003785L NO20003785L (no) 2000-07-24
NO327819B1 NO327819B1 (no) 2009-09-28

Family

ID=9522673

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20003785A NO327819B1 (no) 1998-02-06 2000-07-24 Anvendelse av riluzol eller et farmasoytisk akseptabelt salt derav

Country Status (18)

Country Link
US (1) US6245791B1 (no)
EP (1) EP1052989B1 (no)
JP (1) JP5127092B2 (no)
KR (1) KR100574378B1 (no)
AT (1) ATE245982T1 (no)
AU (1) AU761978B2 (no)
CA (1) CA2319686C (no)
DE (1) DE69909970T2 (no)
DK (1) DK1052989T3 (no)
EA (1) EA002676B1 (no)
ES (1) ES2199541T3 (no)
FR (1) FR2774592B1 (no)
IL (2) IL137608A0 (no)
NO (1) NO327819B1 (no)
NZ (1) NZ506124A (no)
PT (1) PT1052989E (no)
WO (1) WO1999039710A1 (no)
ZA (1) ZA99740B (no)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6872739B1 (en) 1999-06-04 2005-03-29 Vereniging Voor Christelijk Wetenshappelikjk Onderwijs Use of riluzole for the treatment of multiple sclerosis
US10639298B2 (en) * 2015-03-03 2020-05-05 Biohaven Therapeutics Ltd. Prodrugs of riluzole and their method of use
MD3706739T2 (ro) * 2017-11-12 2025-02-28 Biohaven Therapeutics Ltd Utilizarea promedicamentelor de riluzol pentru tratarea ataxiei
US12364687B2 (en) * 2018-05-27 2025-07-22 Biohaven Therapeutics Ltd. Use of riluzole oral disintegrating tablets for treating diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2043070T3 (es) * 1988-12-15 1993-12-16 Rhone Poulenc Sante Procedimiento para la preparacion de derivados de la benzotiazolamina-2.
FR2700117B1 (fr) * 1993-01-07 1995-02-03 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement de la maladie de Parkinson et des syndromes parkinsoniens.
FR2702148B1 (fr) * 1993-03-05 1995-04-07 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement du neuro-sida.
FR2714828B1 (fr) * 1994-01-12 1996-02-02 Rhone Poulenc Rorer Sa Application du riluzole dans le traitement des maladies mitochondriales.
FR2726271B1 (fr) * 1994-10-26 1996-12-06 Rhone Poulenc Rorer Sa Derives de 6-polyfluoroalcoxy-2-aminobenzothiazole

Also Published As

Publication number Publication date
CA2319686A1 (fr) 1999-08-12
NO327819B1 (no) 2009-09-28
ES2199541T3 (es) 2004-02-16
FR2774592A1 (fr) 1999-08-13
IL137608A0 (en) 2001-07-24
KR20010040671A (ko) 2001-05-15
WO1999039710A1 (fr) 1999-08-12
NZ506124A (en) 2003-07-25
AU761978B2 (en) 2003-06-12
JP5127092B2 (ja) 2013-01-23
DE69909970T2 (de) 2004-05-27
PT1052989E (pt) 2003-12-31
DK1052989T3 (da) 2003-11-17
NO20003785L (no) 2000-07-24
DE69909970D1 (de) 2003-09-04
FR2774592B1 (fr) 2000-03-17
ATE245982T1 (de) 2003-08-15
US6245791B1 (en) 2001-06-12
CA2319686C (fr) 2009-06-23
AU2171199A (en) 1999-08-23
ZA99740B (en) 1999-08-02
EP1052989B1 (fr) 2003-07-30
IL137608A (en) 2006-09-05
KR100574378B1 (ko) 2006-04-26
EA002676B1 (ru) 2002-08-29
JP2002502819A (ja) 2002-01-29
EP1052989A1 (fr) 2000-11-22
EA200000816A1 (ru) 2001-02-26

Similar Documents

Publication Publication Date Title
GB0225475D0 (en) Therapeutic agents
MY130580A (en) Oxalylamino-benzofuran and benzothienyl derivatives
AP2005003350A0 (en) 3-(3,5-dioxo-4,5-dihydro-3H-(1,2,4) triazin-2-yl)-benzamide derivatives as p2X7 -inhibitors for the treatment of inflammatory diseases.
WO2005021495A3 (en) Quaternary salt derivatives of 1,4-diphenylazetidin-2-ones
ES2156287T3 (es) Derivados de difenilmetilen piperidina.
NO953370L (no) Anvendelse av riluzol ved behandling av neuro-AIDS
NO20005290D0 (no) Riluzol- og levodopa kombinasjoner for behandling av Parkinsons sykdom
PE20030061A1 (es) 1-biaril-1,8-naftiridin-4-ona como inhibidores de fosfodiesterasa-4
BR0017157A (pt) Derivados de 6-hidroxi-indazol para o tratamento de glaucoma
BG106293A (en) Method of inhibiting amyloid protein aggregation and imaging amyloid deposits
BR0214020A (pt) Método para tratar fibrose cìstica
FI974640A7 (fi) Migreenin hoitoon tarkoitetut 1,6-disubstituoidut isokromaanit
NO20003785L (no) Anvendelse av 2-amino-6-trifluormetoksy-benzotiazol for prevensjon eller terapi av cerebellum dysfunksjon
DE69512310D1 (de) Glukopyranosid-Benzothiophene
PT1183046E (pt) Derivado de aminotetralina para a terapia de doencas cardiovasculares
IT1289154B1 (it) Derivati di isoflavone loro preparazione e loro impiego terapeutico
SE9602416D0 (sv) New forms of an organic salt of N'N-diacetylcystine
EA200200750A1 (ru) Новое терапевтическое применение еноксапарина
MX9604692A (es) Derivados de quinoxalina para el tratamiento de tinnitus.
SV2001000202A (es) Uso de (-)-5-ceto-2-n,n-d1-n-propilamino-tetrahidrotetralina para el tratamiento del mal de parkinson
SE9501773D0 (sv) New use
UY26405A1 (es) Método para tratar el mal de parkinson a través de la administración de (-)-5-ceto-2-n,n-d1-n-propilamino-tetrahidrotetralina.
ECSP003725A (es) Metodo para tratar el mal de parkinson a travez de la administracion de (-) -5- ceto-2-n, n-d1-n-propilamino-tetrahidrotetralina

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees